<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700606</url>
  </required_header>
  <id_info>
    <org_study_id>HFNC</org_study_id>
    <nct_id>NCT03700606</nct_id>
  </id_info>
  <brief_title>Physiological Changes With High-Flow Nasal Cannula</brief_title>
  <official_title>Physiological Changes With High-Flow Nasal Cannula Compared to Nasal CPAP in Extremely Low Birth Weight Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure changes in physiologic parameters in extremely low birthweight (ELBW) infants on
      high-flow nasal cannula compared to nasal continuous positive airway pressure (nCPAP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent is obtained, eligible infants who are stable on nCPAP therapy of 5-7
      cm H20 achieved with a ventilator, an underwater &quot;bubble&quot; system, or a variable-flow device
      will be enrolled.

      All subjects will have physiologic data and electrical impedance tomography collected at:

        1. Baseline nCPAP for 15 minutes

        2. Upon transition to high flow nasal cannula at 8 LPM for 6 hours. Data collection is
           obtained after infant is calm for 15 minutes at the beginning and end of this 6 hour
           period

        3. Then upon return to baseline NCPAP for a final 15 minutes of data collection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% Unventilated Lung</measure>
    <time_frame>Through study completion, an average of 30 days</time_frame>
    <description>Atelectasis will be calculated using the percentage of the lung fields that are not engaged in tidal volume.(VT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Center of Ventilation (CoV)</measure>
    <time_frame>Through study completion, an average of 30 days</time_frame>
    <description>numeric value that describes the geographic point within the thorax that represents the statistical center of VT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-expiratory lung volume</measure>
    <time_frame>Through study completion, an average of 30 days</time_frame>
    <description>% of total VT within 8 lung regions, relative change in uncalibrated aeration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Respiratory Distress Syndrome in Premature Infant</condition>
  <arm_group>
    <arm_group_label>Nasal CPAP - Period 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible infants stable on high flow nasal cannula (nCPAP) therapy of 5-7 cm H20 achieved with a ventilator, an underwater &quot;bubble&quot; system, or a variable-flow device will be enrolled. A data acquisition cart will be placed at the subject's bedside to collect hemodynamic and respiratory parameters measured including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices. A neonatal chest belt, sized to the infant's chest circumference (nipple level) using warmed ultrasound gel applied to the belt beforehand, will collect regional lung volume measurements using electrical impedance tomography (EIT). Subject video recording will capture apnea events and the interventions used to resolve them such as positive pressure ventilation, repositioning, or stimulation. Data will be collected for 15 minutes on nCPAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Flow Nasal Cannula (HFNC) - Period 2 &amp; 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory support will be crossed over to a HFNC Optiflow Jr 2 (Fisher &amp; Paykel Healthcare, Auckland, New Zealand) at a flow rate of 8 LPM. The size of the nasal cannula will be determined according to the manufacturer's instructions in order to maintain a leak at the nares. Identical data collection will occur for two 15 minute periods on HFNC, at the beginning and end of the six hour Study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal CPAP - Period 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After 6 hours of HFNC of 8 LPM, or sooner if the infant meets failure criteria, the infant will then be crossed back to the nCPAP device and at the settings previously utilized in Study Period 1. The infant will remain on the nCPAP device with identical data collection for 15 minutes. The total duration of the study and data collection will be 8 hours. The infant's body position will be similar for each lung volume measurement during the study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High flow nasal cannula</intervention_name>
    <description>8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.</description>
    <arm_group_label>High Flow Nasal Cannula (HFNC) - Period 2 &amp; 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasal CPAP</intervention_name>
    <description>Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.</description>
    <arm_group_label>Nasal CPAP - Period 1</arm_group_label>
    <arm_group_label>Nasal CPAP - Period 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  23 to 28+6 weeks gestational age at birth

          -  Corrected gestational age less than or equal to 30 weeks

          -  Over 72 hours of life

          -  Stable on Nasal CPAP of 5-7cm H20

          -  Hemodynamically stable

          -  Tolerating routine handling

          -  Nares size appropriate for Fisher &amp; Paykel Optiflow Jr 2 HFNC size XS or small

          -  Successfully extubated for 12 hours after administration of surfactant

          -  Caffeine Citrate at a maintenance dose of 5 to 10 mg /kg

          -  Transcutaneous monitoring in place

          -  Stable blood gas (pH&gt;/= 7.25 and PaCO2 &lt;60 mmHg torr)

        Exclusion Criteria:

          -  Prior pneumothorax or evidence of pulmonary interstitial emphysema.

          -  Prior or current pulmonary hemorrhage

          -  Congenital airway malformations

          -  Major cardiopulmonary malformations

          -  Congenital Diaphragmatic hernia or untreated bowel obstruction

          -  Poor respiratory drive unresponsive to CPAP therapy

          -  Requirement of a nCPAP of &gt;8 cmH20 or FiO2 &gt; 0.3 to maintain oxygen saturations
             between 90-95 percent.

          -  Receiving positive pressure breaths or SIPAP on prongs

          -  Conflicting clinical trial

          -  Clinically unstable per physician discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>29 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anup Katheria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anup Katheria, MD</last_name>
    <phone>858-939-4170</phone>
    <email>anup.katheria@sharp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Ines, RCP-RRT</last_name>
    <phone>858-939-4136</phone>
    <email>felix.ines@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women &amp; Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anup Katheria, MD</last_name>
      <phone>858-939-4170</phone>
      <email>anup.katheria@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Felix Ines, RCP-RRT</last_name>
      <phone>858-939-4136</phone>
      <email>felix.ines@sharp.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>Anup Katheria, M.D.</investigator_full_name>
    <investigator_title>Director Neonatal Research Institute</investigator_title>
  </responsible_party>
  <keyword>high flow nasal cannula</keyword>
  <keyword>nasal cpap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

